Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer

Results from a phase II study

G. Bolis, S. Danese, S. Tateo, E. Rabaiotti, G. D'Agostino, C. Merisio, G. Scarfone, G. Polverino, F. Parazzini

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

To compare the effect of epidoxorubicin given for 4 months versus no treatment in the survival of patients with advanced ovarian cancer and complete pathologic response after first-line surgery and chemotherapy with platinum-based schedules, we conducted a multicenter randomized clinical trial. Patients with histologic diagnosis of epithelial ovarian cancer FIGO stage III or IV at first diagnosis; complete pathologic response at second-look laparotomy/laparoscopy or complete clinic response; and those who have had first-line therapy including surgery and one regimen containing cisplatin or carboplatinum were eligible for the study and were randomly allocated to epidoxorubicin 120 mg/sqm or no treatment. A total of 64 women were allocated to epidoxorubicin and 74 to no treatment. There were 20 and 19 deaths, respectively, in the epidoxorubicin and no-treatment groups. The 3-year percent overall survival was 79.0% and 78.7%, respectively, in the no-treatment and epidoxorubicin groups (log-rank test, P = 0.93).

Original languageEnglish
Pages (from-to)74-78
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume16
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Ovarian Neoplasms
Therapeutics
Epirubicin
Survival
Platinum
Laparoscopy
Laparotomy
Cisplatin
Appointments and Schedules
Randomized Controlled Trials
Drug Therapy

Keywords

  • Consolidation treatment
  • Epidoxorubicin
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

Cite this

Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer : Results from a phase II study. / Bolis, G.; Danese, S.; Tateo, S.; Rabaiotti, E.; D'Agostino, G.; Merisio, C.; Scarfone, G.; Polverino, G.; Parazzini, F.

In: International Journal of Gynecological Cancer, Vol. 16, No. SUPPL. 1, 02.2006, p. 74-78.

Research output: Contribution to journalArticle

@article{7af7faa19cc24f69a5dc2fd76c43fe1e,
title = "Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: Results from a phase II study",
abstract = "To compare the effect of epidoxorubicin given for 4 months versus no treatment in the survival of patients with advanced ovarian cancer and complete pathologic response after first-line surgery and chemotherapy with platinum-based schedules, we conducted a multicenter randomized clinical trial. Patients with histologic diagnosis of epithelial ovarian cancer FIGO stage III or IV at first diagnosis; complete pathologic response at second-look laparotomy/laparoscopy or complete clinic response; and those who have had first-line therapy including surgery and one regimen containing cisplatin or carboplatinum were eligible for the study and were randomly allocated to epidoxorubicin 120 mg/sqm or no treatment. A total of 64 women were allocated to epidoxorubicin and 74 to no treatment. There were 20 and 19 deaths, respectively, in the epidoxorubicin and no-treatment groups. The 3-year percent overall survival was 79.0{\%} and 78.7{\%}, respectively, in the no-treatment and epidoxorubicin groups (log-rank test, P = 0.93).",
keywords = "Consolidation treatment, Epidoxorubicin, Ovarian cancer",
author = "G. Bolis and S. Danese and S. Tateo and E. Rabaiotti and G. D'Agostino and C. Merisio and G. Scarfone and G. Polverino and F. Parazzini",
year = "2006",
month = "2",
doi = "10.1111/j.1525-1438.2006.00313.x",
language = "English",
volume = "16",
pages = "74--78",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer

T2 - Results from a phase II study

AU - Bolis, G.

AU - Danese, S.

AU - Tateo, S.

AU - Rabaiotti, E.

AU - D'Agostino, G.

AU - Merisio, C.

AU - Scarfone, G.

AU - Polverino, G.

AU - Parazzini, F.

PY - 2006/2

Y1 - 2006/2

N2 - To compare the effect of epidoxorubicin given for 4 months versus no treatment in the survival of patients with advanced ovarian cancer and complete pathologic response after first-line surgery and chemotherapy with platinum-based schedules, we conducted a multicenter randomized clinical trial. Patients with histologic diagnosis of epithelial ovarian cancer FIGO stage III or IV at first diagnosis; complete pathologic response at second-look laparotomy/laparoscopy or complete clinic response; and those who have had first-line therapy including surgery and one regimen containing cisplatin or carboplatinum were eligible for the study and were randomly allocated to epidoxorubicin 120 mg/sqm or no treatment. A total of 64 women were allocated to epidoxorubicin and 74 to no treatment. There were 20 and 19 deaths, respectively, in the epidoxorubicin and no-treatment groups. The 3-year percent overall survival was 79.0% and 78.7%, respectively, in the no-treatment and epidoxorubicin groups (log-rank test, P = 0.93).

AB - To compare the effect of epidoxorubicin given for 4 months versus no treatment in the survival of patients with advanced ovarian cancer and complete pathologic response after first-line surgery and chemotherapy with platinum-based schedules, we conducted a multicenter randomized clinical trial. Patients with histologic diagnosis of epithelial ovarian cancer FIGO stage III or IV at first diagnosis; complete pathologic response at second-look laparotomy/laparoscopy or complete clinic response; and those who have had first-line therapy including surgery and one regimen containing cisplatin or carboplatinum were eligible for the study and were randomly allocated to epidoxorubicin 120 mg/sqm or no treatment. A total of 64 women were allocated to epidoxorubicin and 74 to no treatment. There were 20 and 19 deaths, respectively, in the epidoxorubicin and no-treatment groups. The 3-year percent overall survival was 79.0% and 78.7%, respectively, in the no-treatment and epidoxorubicin groups (log-rank test, P = 0.93).

KW - Consolidation treatment

KW - Epidoxorubicin

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=33645356202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645356202&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2006.00313.x

DO - 10.1111/j.1525-1438.2006.00313.x

M3 - Article

VL - 16

SP - 74

EP - 78

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - SUPPL. 1

ER -